Details of Disease

General Information of Disease (ID: DISVHK7H)

Disease Name	Venous thrombosis
Synonyms	venous thrombosis; prothrombin 20210G>A thrombophilia; thromboembolism, susceptibility to; prothrombin G20210A thrombophilia; thrombophilia due to factor 2 defect; THPH1; thrombosis, protection against; hyperprothrombinemia; factor II-related thrombophilia; Venous thromboembolism; thrombophilia 1 due to thrombin defect; venous thromboembolism, susceptibility to; thrombophilia due to thrombin defect; prothrombin-related thrombophilia; prothrombin thrombophilia; venous thrombosis, protection against
Disease Class	BA43: Coronary thrombosis
Definition	The formation of a blood clot (thrombus) in the lumen of a vein.
Disease Hierarchy	DISFG8KS: Inherited thrombophilia DISVHK7H: Venous thrombosis
ICD Code	ICD-11 ICD-11: BA43 ICD-10 ICD-10: I24.0
Disease Identifiers	MONDO ID MONDO_0008559 MESH ID D020246 UMLS CUI C3160733 OMIM ID 188050 MedGen ID 463623 HPO ID HP:0004936 SNOMED CT ID 111293003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ardeparin	DMYRX8B	Approved	Small molecular drug	[1]
Fondaparinux sodium	DMWS3FH	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Heparin	DM4ZP3W	Phase 2/3 Trial	Small molecular drug	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SR-123781A	DM5WQ2U	Phase 2/3	NA	[4]
REG2	DMJMU56	Phase 1	NA	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
F2	TT6L509	Strong	CausalMutation	[6]
F2	TT6L509	Definitive	Autosomal dominant	[7]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
F2	OTNFSM49	Definitive	Autosomal dominant	[7]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6811).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
4	ClinicalTrials.gov (NCT00338897) Dose Ranging Study in Elective Total Hip Replacement Surgery. U.S. National Institutes of Health.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019932)
6	A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice.Biochim Biophys Acta. 2013 Jun;1832(6):729-41. doi: 10.1016/j.bbadis.2013.02.009. Epub 2013 Feb 18.
7	Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.